うっ血性心不全（CHF）の世界市場レポート 2025年

うっ血性心不全（CHF）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.9％で223億1,000万米ドルに成長します。予測期間においては、デジタルヘルスソリューションの採用の増加、高血圧の有病率の増加、肥満率の増加、患者の転帰の改善、個別化医療への注目の高まりなどが成長の原動力になると予想されます。予測期間の主な動向には、診断技術、治療オプション、画像技術、治療アプローチの革新、ウェアラブル健康機器の開発などの進歩が含まれます。

心血管系患者の増加がうっ血性心不全（CHF）市場の成長を牽引すると予想されます。心血管系の健康は、心臓と血管、および血液を循環させ身体全体の健康を維持する役割に関係します。心血管疾患の増加は、座りがちなライフスタイル、食生活の乱れ、高齢化、都市化などの要因に起因しており、これらすべてが高度なヘルスケアや治療オプションに対する需要の高まりにつながっています。CHFは、心臓の効率を高め、症状を緩和し、合併症を予防し、患者のケアと全体的な健康を改善する、的を絞ったソリューションを提供します。例えば、2023年1月、米国心臓病学会（American College of Cardiology）は、2022年の心血管疾患患者が1,980万人に達したと報告しました。さらに、東欧の死亡率が最も高く、人口10万人当たり553人が死亡しました。その結果、心血管疾患の増加がCHF市場の成長に拍車をかけています。

CHF市場の各企業は、心機能を強化しCHF患者のQOLを向上させる効果的な治療オプションを提供するため、単回冠動脈内注入療法などのイノベーションを優先しています。単回冠動脈内注入療法は、冠動脈に直接薬剤を注入するもので、CHFのような病態を的確に治療するために心臓を標的としています。例えば、2024年1月、ドイツの製薬会社バイエル社と米国のバイオテクノロジー企業アスクレピオス・バイオファーマシューティカル社は、CHFの遺伝子治療薬AB-1002のGenePHIT第II相試験を開始しました。この治療法は非虚血性心筋症を対象としたもので、遺伝子治療によるCHF治療の飛躍的進歩の可能性を示すものです。この試験は適応症、二重盲検、プラセボ対照で、少なくとも4週間以上医学的に安定しており、左室駆出率が15％から35％の患者90人から150人が登録されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界うっ血性心不全（CHF） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のうっ血性心不全（CHF）市場：成長率分析
• 世界のうっ血性心不全（CHF）市場の実績：規模と成長, 2019-2024
• 世界のうっ血性心不全（CHF）市場の予測：規模と成長, 2024-2029, 2034F
• 世界うっ血性心不全（CHF）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のうっ血性心不全（CHF）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 収縮期心不全
• 拡張不全
• 左心不全
• 右心不全
• 世界のうっ血性心不全（CHF）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• 手術
• 世界のうっ血性心不全（CHF）市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心電図
• 心エコー検査
• 磁気共鳴画像法（MRI）
• ストレステスト
• 血液検査
• 心臓カテーテル検査
• その他の診断
• 世界のうっ血性心不全（CHF）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のうっ血性心不全（CHF）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• 在宅ケア設定
• 世界のうっ血性心不全（CHF）市場収縮期心不全の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 駆出率低下（HFrEF）
• 軽度から中等度の駆出率低下
• 世界のうっ血性心不全（CHF）市場、拡張期心不全の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 駆出率保持型（HFpEF）
• 境界性駆出率（HFpEF）
• 世界のうっ血性心不全（CHF）市場左心不全の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性左心不全
• 慢性左心不全
• 世界のうっ血性心不全（CHF）市場右心不全の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性右心不全
• 慢性右心不全

第7章 地域別・国別分析

• 世界のうっ血性心不全（CHF）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のうっ血性心不全（CHF）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• うっ血性心不全（CHF）市場：競合情勢
• うっ血性心不全（CHF）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Novartis AG.
• Medtronic Plc
• Eli Lilly and Company
• Canon Medical Systems Corporation
• Novo Nordisk A/S
• Jarvik Heart Inc.
• Boston Scientific Corporation
• Applied Molecular Genetics Inc.
• Biotronik SE & Co. KG
• Exelixis Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd.
• LivaNova

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• うっ血性心不全（CHF）市場2029：新たな機会を提供する国
• うっ血性心不全（CHF）市場2029：新たな機会を提供するセグメント
• うっ血性心不全（CHF）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Congestive heart failure (CHF) is a chronic and progressive condition in which the heart's ability to effectively pump blood is compromised, leading to fluid buildup in the lungs, heart, liver, and other areas of the body. This results in symptoms such as shortness of breath, fatigue, swelling, and difficulty with daily activities, ultimately affecting overall quality of life and necessitating continuous medical management and treatment.

The main types of congestive heart failure (CHF) include systolic heart failure, diastolic heart failure, left-sided heart failure, and right-sided heart failure. Systolic heart failure occurs when the heart muscle is unable to pump blood efficiently, causing poor circulation. Treatment options include medications and surgery, with diagnostic methods such as electrocardiograms, echocardiograms, magnetic resonance imaging (MRI), stress tests, blood tests, and cardiac catheterization. These treatments and diagnostics are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies. They are used by a wide range of end-users, such as hospitals, specialty clinics, ambulatory surgical centers, and homecare settings.

The congestive heart failure (CHF) market research report is one of a series of new reports from The Business Research Company that provides Congestive Heart Failure (CHF) market statistics, including Congestive Heart Failure (CHF) industry global market size, regional shares, competitors with a Congestive Heart Failure (CHF) market share, detailed Congestive Heart Failure (CHF) market segments, market trends and opportunities, and any further data you may need to thrive in the Congestive Heart Failure (CHF) industry. This Congestive Heart Failure (CHF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The congestive heart failure (CHF) market size has grown strongly in recent years. It will grow from $15.94 billion in 2024 to $17.10 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be attributed to the high prevalence of an aging population, the increasing incidence of cardiovascular diseases, growing awareness of heart health, rising healthcare expenditures, and the growing demand for remote patient monitoring.

The congestive heart failure (CHF) market size is expected to see strong growth in the next few years. It will grow to $22.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. In the forecast period, growth is expected to be driven by the rising adoption of digital health solutions, the increasing prevalence of hypertension, the growing rates of obesity, improved patient outcomes, and a heightened focus on personalized medicine. Key trends in the forecast period include advancements in diagnostic technologies, treatment options, imaging technologies, innovations in therapeutic approaches, and developments in wearable health devices.

The rise in cardiovascular patients is expected to drive the growth of the congestive heart failure (CHF) market. Cardiovascular health pertains to the heart and blood vessels, and their role in circulating blood and maintaining the body's overall health. The increase in cardiovascular cases is attributed to factors such as sedentary lifestyles, poor dietary habits, aging populations, and urbanization, all of which contribute to a higher demand for advanced healthcare and treatment options. CHF offers targeted solutions that enhance heart efficiency, alleviate symptoms, and prevent complications, improving patient care and overall health. For instance, in January 2023, the American College of Cardiology reported that cardiovascular disease cases reached 19.8 million in 2022. Additionally, Eastern Europe had the highest mortality rate, with 553 deaths per 100,000 people. As a result, the rise in cardiovascular cases is fueling growth in the CHF market.

Companies in the CHF market are prioritizing innovations, such as single intracoronary infusion therapies, to provide effective treatment options that enhance heart function and improve the quality of life for CHF patients. Single intracoronary infusion involves delivering medication directly into the coronary artery, targeting the heart for precise treatment of conditions such as CHF. For example, in January 2024, Bayer AG, a German pharmaceutical company, and Asklepios Biopharmaceutical, Inc., a U.S.-based biotechnology company, launched the GenePHIT Phase II trial for AB-1002, a gene therapy for CHF. This approach targets non-ischemic cardiomyopathy and represents a potential breakthrough in CHF treatment through genetic solutions. The trial, which is adaptive, double-blind, and placebo-controlled, will enroll between 90 and 150 participants who have been medically stable for at least four weeks and have a left ventricular ejection fraction between 15% and 35%.

In October 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, acquired V-Wave Ltd., an Israel-based company focused on developing innovative treatments for congestive heart failure. This acquisition strengthens Johnson & Johnson's cardiovascular MedTech portfolio, particularly in heart failure care, with the Ventura Interatrial Shunt being one of the key solutions offered by V-Wave Ltd.

Major players in the congestive heart failure (chf) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG., Medtronic Plc, Eli Lilly and Company, Canon Medical Systems Corporation, Novo Nordisk A/S, Jarvik Heart Inc., Boston Scientific Corporation, Applied Molecular Genetics Inc., Biotronik SE & Co. KG, Exelixis Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., LivaNova

North America was the largest region in the congestive heart failure (CHF) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in congestive heart failure (CHF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the congestive heart failure (CHF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The congestive heart failure (CHF) market consists of revenues earned by entities by providing cardiac treatment, hemodynamic monitoring, and therapeutic services. The market value includes the value of related goods such as diagnostic tools, monitoring devices, and support services. The congestive heart failure (CHF) market also includes sales of diagnostic tools, and testing kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Congestive Heart Failure (CHF) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on congestive heart failure (chf) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for congestive heart failure (chf) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The congestive heart failure (chf) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Systolic Heart Failure; Diastolic Failure; Left-Sided Heart Failure; Right-Sided Heart Failure
• 2) By Treatment: Medication; Surgery
• 3) By Diagnosis: Electrocardiogram; Echocardiogram; Magnetic Resonance Imaging (MRI); Stress Test; Blood Tests; Cardiac Catheterization; Other Diagnosis
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Homecare Settings
• Subsegments:
• 1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF); Mild-to-moderate Reduced Ejection Fraction
• 2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF); Borderline Ejection Fraction (HFpEF)
• 3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure; Chronic Left-Sided Heart Failure
• 4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure; Chronic Right-Sided Heart Failure
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Inc.; Boehringer Ingelheim International GmbH; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Congestive Heart Failure (CHF) Market Characteristics

3. Congestive Heart Failure (CHF) Market Trends And Strategies

4. Congestive Heart Failure (CHF) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Congestive Heart Failure (CHF) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Congestive Heart Failure (CHF) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Congestive Heart Failure (CHF) Market Growth Rate Analysis
• 5.4. Global Congestive Heart Failure (CHF) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Congestive Heart Failure (CHF) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Congestive Heart Failure (CHF) Total Addressable Market (TAM)

6. Congestive Heart Failure (CHF) Market Segmentation

• 6.1. Global Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systolic Heart Failure
• Diastolic Failure
• Left-Sided Heart Failure
• Right-Sided Heart Failure
• 6.2. Global Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• 6.3. Global Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Electrocardiogram
• Echocardiogram
• Magnetic Resonance Imaging (MRI)
• Stress Test
• Blood Tests
• Cardiac Catheterization
• Other Diagnosis
• 6.4. Global Congestive Heart Failure (CHF) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Congestive Heart Failure (CHF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• 6.6. Global Congestive Heart Failure (CHF) Market, Sub-Segmentation Of Systolic Heart Failure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reduced Ejection Fraction (HFrEF)
• Mild-to-moderate Reduced Ejection Fraction
• 6.7. Global Congestive Heart Failure (CHF) Market, Sub-Segmentation Of Diastolic Heart Failure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preserved Ejection Fraction (HFpEF)
• Borderline Ejection Fraction (HFpEF)
• 6.8. Global Congestive Heart Failure (CHF) Market, Sub-Segmentation Of Left-Sided Heart Failure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Left-Sided Heart Failure
• Chronic Left-Sided Heart Failure
• 6.9. Global Congestive Heart Failure (CHF) Market, Sub-Segmentation Of Right-Sided Heart Failure, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Right-Sided Heart Failure
• Chronic Right-Sided Heart Failure

7. Congestive Heart Failure (CHF) Market Regional And Country Analysis

• 7.1. Global Congestive Heart Failure (CHF) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Congestive Heart Failure (CHF) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Congestive Heart Failure (CHF) Market

• 8.1. Asia-Pacific Congestive Heart Failure (CHF) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Congestive Heart Failure (CHF) Market

• 9.1. China Congestive Heart Failure (CHF) Market Overview
• 9.2. China Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Congestive Heart Failure (CHF) Market

• 10.1. India Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Congestive Heart Failure (CHF) Market

• 11.1. Japan Congestive Heart Failure (CHF) Market Overview
• 11.2. Japan Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Congestive Heart Failure (CHF) Market

• 12.1. Australia Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Congestive Heart Failure (CHF) Market

• 13.1. Indonesia Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Congestive Heart Failure (CHF) Market

• 14.1. South Korea Congestive Heart Failure (CHF) Market Overview
• 14.2. South Korea Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Congestive Heart Failure (CHF) Market

• 15.1. Western Europe Congestive Heart Failure (CHF) Market Overview
• 15.2. Western Europe Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Congestive Heart Failure (CHF) Market

• 16.1. UK Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Congestive Heart Failure (CHF) Market

• 17.1. Germany Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Congestive Heart Failure (CHF) Market

• 18.1. France Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Congestive Heart Failure (CHF) Market

• 19.1. Italy Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Congestive Heart Failure (CHF) Market

• 20.1. Spain Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Congestive Heart Failure (CHF) Market

• 21.1. Eastern Europe Congestive Heart Failure (CHF) Market Overview
• 21.2. Eastern Europe Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Congestive Heart Failure (CHF) Market

• 22.1. Russia Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Congestive Heart Failure (CHF) Market

• 23.1. North America Congestive Heart Failure (CHF) Market Overview
• 23.2. North America Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Congestive Heart Failure (CHF) Market

• 24.1. USA Congestive Heart Failure (CHF) Market Overview
• 24.2. USA Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Congestive Heart Failure (CHF) Market

• 25.1. Canada Congestive Heart Failure (CHF) Market Overview
• 25.2. Canada Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Congestive Heart Failure (CHF) Market

• 26.1. South America Congestive Heart Failure (CHF) Market Overview
• 26.2. South America Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Congestive Heart Failure (CHF) Market

• 27.1. Brazil Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Congestive Heart Failure (CHF) Market

• 28.1. Middle East Congestive Heart Failure (CHF) Market Overview
• 28.2. Middle East Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Congestive Heart Failure (CHF) Market

• 29.1. Africa Congestive Heart Failure (CHF) Market Overview
• 29.2. Africa Congestive Heart Failure (CHF) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Congestive Heart Failure (CHF) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Congestive Heart Failure (CHF) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Congestive Heart Failure (CHF) Market Competitive Landscape And Company Profiles

• 30.1. Congestive Heart Failure (CHF) Market Competitive Landscape
• 30.2. Congestive Heart Failure (CHF) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Congestive Heart Failure (CHF) Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. Abbott Laboratories
• 31.4. Novartis AG.
• 31.5. Medtronic Plc
• 31.6. Eli Lilly and Company
• 31.7. Canon Medical Systems Corporation
• 31.8. Novo Nordisk A/S
• 31.9. Jarvik Heart Inc.
• 31.10. Boston Scientific Corporation
• 31.11. Applied Molecular Genetics Inc.
• 31.12. Biotronik SE & Co. KG
• 31.13. Exelixis Pharmaceuticals Inc.
• 31.14. Otsuka Pharmaceutical Co. Ltd.
• 31.15. LivaNova

32. Global Congestive Heart Failure (CHF) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Congestive Heart Failure (CHF) Market

34. Recent Developments In The Congestive Heart Failure (CHF) Market

35. Congestive Heart Failure (CHF) Market High Potential Countries, Segments and Strategies

• 35.1 Congestive Heart Failure (CHF) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Congestive Heart Failure (CHF) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Congestive Heart Failure (CHF) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer